FDA finally gets a public list of what's in your food
S. 3122 — Better FDA Act of 2025 · Filed by Roger Marshall (R-KS) · 3 cosponsors · Introduced Nov 6, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the FDA to create and maintain a public list of food substances that are 'generally recognized as safe' (GRAS), and mandates that companies notify the FDA before using new GRAS substances in food. Existing GRAS substances have 2 years to be listed; new ones must be reported 120 days before use. If the FDA doesn't act within 180 days, substances are automatically deemed safe and added to the list. The bill also creates a postmarket review process allowing the FDA to re-evaluate GRAS substances, food additives, and color additives if safety concerns emerge.
Why we flagged it
The bill's core function is to formalize and publicize the FDA's oversight of GRAS substances—a category that has operated largely outside public view since 1958. It shifts from a passive, company-initiated notification system to an active FDA-maintained registry with mandatory reporting and postmarket review authority.
What the text implies
- The automatic-listing provision (substances deemed safe if FDA doesn't act within 180 days) may create a de facto approval mechanism that pressures the FDA to act quickly, potentially favoring companies over thorough safety review if FDA resources are constrained.
- Postmarket review authority in Section 409B allows the FDA to reclassify GRAS substances as food additives subject to stricter section 409 requirements, retroactively changing the regulatory status of substances already in use—potentially disrupting supply chains and imposing compliance costs on manufacturers.
The full analysis lists 5 implications of this text.
Who stands to gain
pharmaceutical companies (regulatory clarity and potential market access for food-derived ingredient; food manufacturers (transparency reduces liability from unlisted substances; automatic approval mech; contract research organizations (increased demand for safety studies to support GRAS notices)